Which hedge funds own RYTM? RHYTHM PHARMACEUTICALS INC, Q2 2026 13F holders
57 tracked hedge funds disclosed a position in RYTM (RHYTHM PHARMACEUTICALS INC) in their Q2 2026 13F filings, worth $2.9bn in total. The largest holder by portfolio weight is Checkpoint Capital L.P. at 33.8% of its book. 14 opened a new position this quarter: Sphera Funds Management Ltd., Duquesne Family Office LLC, Zweig-DiMenna Associates LLC, Cinctive Capital Management LP. 11 exited: Verdad Advisers, LP, PDT Partners, LLC, Fox Run Management, L.L.C..
- 57
- Holders Tracked managers whose filing for the quarter reports a long equity position in the security.
- 14
- New this quarter Holders whose previous filing (at most two quarters earlier) did not report the security.
- 11
- Exited this quarter Tracked managers whose previous filing reported the security and whose filing for the quarter does not.
- $60.9m
- Inflow, new holders Combined value of the positions the new holders reported for the quarter.
- $13.2m
- Outflow, exits Combined value the exiting managers reported for the security in their previous filing.
- $2.9bn
- Combined value Sum of the holders' reported positions in the security.
- 4.6%
- Share of managers holding Holders as a share of tracked managers filing for that quarter. Comparable across the 2024 coverage expansion, where the raw holder count is not.
Holders, Q2 2026
Exited since the previous filing
| Verdad Advisers, LP | 0.2% | $213k |
| PDT Partners, LLC | 0.1% | $2.4m |
| Fox Run Management, L.L.C. | 0.06% | $348k |
| Prelude Capital Management, LLC | 0.06% | $728k |
| Campbell & CO Investment Adviser LLC | 0.03% | $518k |
| Centiva Capital, LP | 0.02% | $348k |
| Balyasny Asset Management L.P. | 0.01% | $4.6m |
| Alyeska Investment Group, L.P. | 0.01% | $2.8m |
| Quantbot Technologies LP | 0.0% | $119k |
| Hudson Bay Capital Management LP | 0.0% | $793k |
| Brevan Howard Capital Management LP | 0.0% | $328k |
Ownership over time
Who discovered RYTM first? Beta
The run: Q2 2022 → Q4 2022, +602%
| Opaleye Management Inc. high conviction | Q3 2022 | 0.7% | +14.0 pts |
| RA Capital Management, L.P. high conviction | Q1 2022 | 0.5% | +9.1 pts |
| Rock Springs Capital Management LP | Q3 2022 | 0.2% | +4.7 pts |
| Frazier Life Sciences Management, L.P. high conviction | Q3 2022 | – | +4.4 pts |
| Parkman Healthcare Partners LLC | Q3 2022 | – | +0.2 pts |
| Prosight Management, LP | Q3 2022 | – | – |
Split-adjusted quarter-end prices, excluding dividends. They describe the stock while each manager held it, not the return it earned.